Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Date:12/9/2008

or acute agitation: speed of onset, reliability of medication delivery and patient preference. The Company believes AZ-004 is a product candidate that has the potential to be the first product, if approved, that would be able to both meet these needs for most agitation sufferers and allow physicians to effectively respond to the potential rapid escalation of an acute agitation episode.

About AZ-004 (Staccato loxapine)

AZ-004 is the combination of Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known generally as antipsychotics. The Staccato system is a hand-held, chemically-heated, single dose inhaler designed to generate and deliver excipient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics. Alexza has now completed five clinical trials with AZ-004, enrolling more than 800 patients, and has announced positive results from all of these studies.

These five studies include a 50 subject Phase 1 study in healthy volunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and pharmacokinetic study in non-agitated schizophrenic patients, a 344 patient Phase 3 study in schizophrenic patients with acute agitation, and a 314 patient Phase 3 study in bipolar disorder patients with acute agitation. Alexza completed an end- of-Phase 2 meeting with the FDA for AZ-004 in September 2007, and believes it has a clear understanding of the development requirements for filing an NDA for AZ-004.

In the previously reported Phase 3 study in agitated schizophrenic patients, both the 5 mg and 10 mg doses of AZ-004 met the primary endpoint of the trial and the key secondary endpoint of the trial, both doses showing a highly statistically significant reduction in agitation in both endpoints, as compared to placebo. The 10 mg dose of AZ-004 exhibited a rapid onset of effect, w
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
2. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Calif., Dec. 16 Frost & ... Bujnoch, looks forward to speaking at the ... taking place on January 9, 2010 in ... the emerging market of consumer-based digital health ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch ...
(Date:12/16/2009)... 16 Savara, Inc., an inhalation drug delivery ... tranche in its Series A financing round, exceeding the ... ,, Funds raised in the Series A round will ... technology. ,, "We now have the runway and ... the NanoCluster technology," said Rob Neville, CEO of Savara. ...
(Date:12/16/2009)... Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), ... non-human primate study of its novel, once-a-day, oral ... of tularemia. A 14-day course of Restanza achieved ... All of the ten animals in the ... (approximate to a human dose of 300 mg) ...
Breaking Medicine Technology:Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 2Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 3Advanced Life Sciences' Restanza Shows 100% Survival in Tularemia Pivotal Animal Study 4Key Lawmakers to Appear in Citizen Led Health Care Forum On PJTV com 51846 1Key Lawmakers to Appear in Citizen Led Health Care Forum On PJTV com 51846 2Key Lawmakers to Appear in Citizen Led Health Care Forum On PJTV com 51846 3Air Quality Action Day Forecast for July 16 in Philadelphia Region 51844 1Air Quality Action Day Forecast for July 16 in Philadelphia Region 51844 2VA Announces 2426 Million Construction Contract for Palo Alto 51841 1
... International, Inc.,(Nasdaq: DATA ), a technology and services ... industry, today reported its,operating results for the first quarter ... 31, 2008, revenue decreased,approximately 41% to $2,088,000 and the ... share on both a basic and diluted basis. These,results ...
... May 8 The Cancer Research Alliance, an,organization comprised ... asking,303 million Americans to exercise their power over cancer ... through Father,s Day., The campaign, dubbed the "Infinite ... everywhere to take matters into their own hands by,joining ...
Other Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5
(Date:12/16/2009)... have myopia now than in the ,70s, study finds ... is more common in the United States than it ... Institute study shows. , Researchers compared National Health and ... participants from 1971 to 1972 and from 8,339 black ... were 12 to 54 years old. , The prevalence ...
(Date:12/16/2009)... week trial bottle sample with purchase of 90-count bottle. , ... ... ImmuneResponse247.com announces a special free offer for a “Free ... Mushroom Formula , with the purchase of a 90-count bottle. ... packaged in FDA approved facilities and blends the 6 most important ...
(Date:12/16/2009)... to announce being presented with the Weatherhead 100 Upstart Award on ... companies in Northeast Ohio and is a testament to hard work, ... , ... (PRWEB) December 16, 2009 -- Request A Test, ... Upstart Award on December 3, 2009. The Weatherhead 100 showcases ...
(Date:12/16/2009)... are rapidly approaching and what would be the perfect gift to ... of course! Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook introduces ... look and feel their best! , ... (PRWEB) December ... of gift does a person get that special woman who has ...
(Date:12/15/2009)... SUMMARY: The U.S. Senate ... and Affordable Care Act that would have helped ... the safe and legal importation of lower priced ... AARP and sponsored by Senators Dorgan, Snowe, McCain, ... helped to bring down the skyrocketing costs of ...
Breaking Medicine News(10 mins):Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3
... pharmaceutical packaging customers new microfilling capabilities for pouches, ... maximum job flexibility and productivity, the Clifton, NJ ... schedule for packaging solid dose preparations, liquids and ... packages, pouches, bottles and cans. , ...
... 10 The growing asthma & allergy friendly(TM) ... and adopted a certification standard and testing protocol ... allergy friendly(TM) Certification Program administered by the Asthma ... with the international research organization, Allergy Standards Limited ...
... The ABLE TO CHOOSE public awareness campaign, www.abletochoose.org ... opinion on people with disabilities, will officially launch February ... ABLE TO CHOOSE campaign invites Virginians to join in ... to people with disabilities," said Heidi Lawyer, Executive Director ...
... With the rising cost of health care, more and ... cost-effective care. During National Wise Health Consumer Month ... to take another look at chiropractic care.February is ... excellent time for Minnesotans to learn about chiropractic care ...
... Freedom (IHF) is warning the public that the economic ... each American to use "an" electronic health record (EHR) ... to add opt-out and patient-consent provisions to ensure true ... line is that if YOU want to control the ...
... - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: ... on Wednesday, February 11, 2009 at 4:30 P.M. EST to ... Cruz, Chairman and Chief Executive Officer of the Company, will ... this period in a press release to be issued prior ...
Other Medicine News:Health News:Compass Pharma Services Offers Microfill Capabilities to Contract Pharmaceutical Packaging Customers 2Health News:Helping to Clear the Air for Consumers - New Certification Standard for HEPA Filters Will Help Millions of People Make More Educated Choices 2Health News:Official Launch of ABLE TO CHOOSE Public Awareness Campaign 2Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 2Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 3Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 4Health News:During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care 5Health News:Economic Stimulus Bill Mandates Electronic Health Records for Every American by 2014 - With No Opt-out Provision 2Health News:Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST 2
ELX50 is a self-contained, user programmable, universal microstrip washer. The ELX50 can be used to wash assays including ELISA, Fluorescence, Chemolumineszenz, RIA, DNA probes and cellular assays....
Fully automatic NRTL and CE certified microplate reader....
Diareader ELX800G...
Elisa strip reader...
Medicine Products: